Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2026-01-04 @ 2:52 PM
Study NCT ID:
NCT06523803
Status:
TERMINATED
Last Update Posted:
2025-10-21
First Post:
2024-07-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 32}}, 'statusModule': {'whyStopped': 'Sponsor decision', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2024-09-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2025-10-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-16', 'studyFirstSubmitDate': '2024-07-22', 'studyFirstSubmitQcDate': '2024-07-22', 'lastUpdatePostDateStruct': {'date': '2025-10-21', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-07-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-09-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of dose-limiting toxicities (DLTs; Part 1)', 'timeFrame': 'Up to 3 weeks', 'description': 'Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW171'}, {'measure': 'Incidence of adverse events (AEs; Parts 1 and 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Number of participants who experienced AEs or serious adverse events (SAEs)'}, {'measure': 'Incidence of cytokine release syndrome (CRS; Parts 1 and 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Number of participants who experienced CRS'}, {'measure': 'Incidence of neurotoxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS; Parts 1 and 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Number of participants who experienced neurotoxicity, including ICANS'}, {'measure': 'Incidence of clinical laboratory abnormalities (Parts 1 and 2)', 'timeFrame': 'Up to approximately 2 years', 'description': "Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0"}, {'measure': 'Confirmed objective response rate (Part 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Number of participants who achieved a best overall response of either confirmed complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1'}], 'secondaryOutcomes': [{'measure': 'Confirmed objective response rate (Part 1)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Number of participants who achieved a best overall response of either confirmed CR or PR during treatment according to RECIST v1.1'}, {'measure': 'Duration of response (DOR; Part 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'The time from the first objective response (CR or PR) to the first documented progressive disease (PD) per RECIST v1.1 or death within 30 days of last dose of study treatment from any cause. Only participants who achieve a confirmed response will be included in the analysis'}, {'measure': 'Progression-free survival (PFS), including 1-year PFS (Part 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'The time from the first dose of study treatment to the date of first documented PD per RECIST v1.1 or death from any cause'}, {'measure': 'Disease control rate (DCR; Part 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'Number of participants who achieved a best response of CR, PR, non-CR/non-PD (for participants who have only non-target lesions), or stable disease (SD) during treatment per RECIST v1.1'}, {'measure': 'Overall survival (OS), including 1-year OS (Part 2)', 'timeFrame': 'Up to approximately 2 years', 'description': 'The time from the first dose of ZW171 until the date of death from any cause'}, {'measure': 'Serum concentration of ZW171 (Parts 1 and 2)', 'timeFrame': 'Up to approximately 7 months', 'description': 'Maximum serum concentration and trough concentration of ZW171'}, {'measure': 'Incidence of anti-drug antibodies (ADAs; Parts 1 and 2)', 'timeFrame': 'Up to approximately 7 months', 'description': 'Number of participants who develop ADAs'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Advanced or Metastatic Cancers', 'ADC', 'Antibody drug conjugate'], 'conditions': ['Mesothelin-expressing Advanced Cancers']}, 'descriptionModule': {'briefSummary': 'This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \\[inoperable\\] and/or metastatic) mesothelin-expressing cancers.', 'detailedDescription': 'Part 1 of the study will evaluate the safety and tolerability of ZW171. Part 2 of the study will evaluate the anti-tumor activity of ZW171 while continuing to evaluate the safety and tolerability.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Pathologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable) and/or metastatic disease. Cancers that are refractory to all available standard of care (SOC) treatment, cancers for which no SOC treatment is available, or the participant cannot tolerate or refuses SOC therapy.\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n* Adequate cardiac left ventricular function, as defined by left ventricular ejection fraction ≥ 50% as determined by either echocardiogram or multigated acquisition scan.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Known additional malignancy that is progressing or that has required active treatment.\n* Undergone prior allogenic tissue (e.g., hematopoietic stem cell) or solid organ transplantation within the last 5 years.\n* Ongoing, clinically significant toxicity (Grade ≥ 2) associated with prior cancer therapies, with the exception of alopecia.\n* Advanced/metastatic, symptomatic, visceral spread, at risk of life-threatening complications in the short-term (including participants with massive uncontrolled effusion \\[pleural, pericardial\\], pulmonary lymphangitis, active unresolved bowel obstruction, massive ascites \\[requiring paracentesis \\>2 times within 2 weeks prior to the first dose\\], and over 50% liver involvement).\n* Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of participants with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment).\n* Active or recurrent clinically significant autoimmune disease requiring systemic high-dose corticosteroids or immunosuppressive drugs."}, 'identificationModule': {'nctId': 'NCT06523803', 'briefTitle': 'A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Zymeworks BC Inc.'}, 'officialTitle': 'A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers', 'orgStudyIdInfo': {'id': 'ZWI-ZW171-101'}, 'secondaryIdInfos': [{'id': '2024-511119-11', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ZW171', 'interventionNames': ['Drug: ZW171']}], 'interventions': [{'name': 'ZW171', 'type': 'DRUG', 'description': 'Administered per protocol requirements', 'armGroupLabels': ['ZW171']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90089', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'University of Southern California - Norris Comprehensive Cancer Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado Health Sciences Center', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Norton Cancer Institute', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '10011', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Icahn School of Medicine at Mount Sinai (ISMMS) - The Blavatnik Family-Chelsea Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'UPMC Hillman Cancer Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Sarah Cannon Research Institute', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '98195', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'University of Washington', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '01307', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Universitaetsklinikum Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '03080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Yonsei University Health System - Severance Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '06351', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'The Catholic University of Korea, Seoul St. Marys Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': 'SE1 9RT', 'city': 'London', 'country': 'United Kingdom', 'facility': "Guys and St Thomas' NHS Foundation Trust", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'The Christie NHS Foundation Trust', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'SW3 6JJ', 'city': 'Sutton', 'country': 'United Kingdom', 'facility': 'Royal Marsden Hospital', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}], 'overallOfficials': [{'name': 'Pranshul Chauhan, MSc, MB, BCh, BAO', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Zymeworks BC Inc.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Zymeworks BC Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}